• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapy and medication isn't effective. A customized treatment could be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into personalized micro-interventions to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet, only half of those with the condition receive treatment. To improve outcomes, healthcare professionals must be able identify and treat patients most likely to benefit from certain treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will gain the most from certain treatments. They are using sensors on mobile phones and a voice assistant incorporating artificial intelligence, and other digital tools. Two grants totaling more than $10 million will be used to determine the biological and behavioral predictors of response.

To date, the majority of research into predictors of depression treatment effectiveness (Hikvisiondb.webcam) has focused on the sociodemographic and clinical aspects. These include factors that affect the demographics such as age, gender and education, clinical characteristics including the severity of symptoms and comorbidities and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data in order to determine mood among individuals. Many studies do not take into consideration the fact that mood can be very different between individuals. Therefore, it is crucial to devise methods that permit the identification and quantification of individual differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behavior and emotions that are unique to each individual.

The team also devised a machine learning algorithm to create dynamic predictors for each person's mood for depression. The algorithm blends these individual variations into a distinct "digital phenotype" for each participant.

The digital phenotype was associated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. The correlation was not strong, however (Pearson r = 0,08, BH adjusted P-value 3.55 x 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 but is often not properly diagnosed and treated. Depression disorders are usually not treated because of the stigma that surrounds them, as well as the lack of effective treatments.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms why is cbt used in the treatment of depression crucial. The current prediction methods rely heavily on clinical interviews, which are unreliable and only detect a few symptoms associated with depression.

Using machine learning to blend continuous digital behavioral phenotypes of a person captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of severity of symptoms has the potential to increase the accuracy of diagnostics and treatment efficacy for depression. Digital phenotypes can be used to provide a wide range of distinct behaviors and activities, which are difficult to record through interviews, and allow for continuous, high-resolution measurements.

The study included University of California Los Angeles students with moderate depression treatment to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics depending on their depression severity. Patients who scored high on the CAT-DI of 35 65 were allocated online support with the help of a peer coach. those with a score of 75 were sent to clinics in-person for psychotherapy.

Participants were asked a set of questions at the beginning of the study regarding their demographics and psychosocial characteristics. These included sex, age and education, as well as work and financial status; whether they were partnered, divorced or single; the frequency of suicidal ideas, intent or attempts; and the frequency at that they consumed alcohol. The CAT-DI was used to rate the severity of depression-related symptoms on a scale from zero to 100. CAT-DI assessments were conducted every other week for the participants who received online support and weekly for those receiving in-person support.

Predictors of Treatment Reaction

Research is focusing on personalization of depression treatment. Many studies are aimed at identifying predictors, which will help clinicians identify the most effective medications for each person. Pharmacogenetics, for instance, identifies genetic variations that determine how the human body metabolizes drugs. This allows doctors to select medications that are likely to be most effective for each patient, while minimizing the time and effort required in trial-and-error treatments and eliminating any side effects that could otherwise slow advancement.

Another promising approach is to build predictive models that incorporate information from clinical studies and neural imaging data. These models can be used to identify the most appropriate combination of variables that is predictive of a particular outcome, like whether or not a particular medication is likely to improve the mood and symptoms. These models can be used to determine the patient's response to treatment, allowing doctors to maximize the effectiveness of their treatment.

A new generation of studies utilizes machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and increase predictive accuracy. These models have been proven to be effective in predicting the outcome of treatment like the response to antidepressants. These methods are becoming more popular in psychiatry and could be the norm in future medical practice.

Research into depression's underlying mechanisms continues, as well as predictive models based on ML. Recent findings suggest that depression is linked to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment for depression will depend on targeted therapies that restore normal function to these circuits.

Internet-delivered interventions can be an option to accomplish this. They can offer a more tailored and individualized experience for patients. One study found that a web-based program was more effective than standard treatment in alleviating symptoms and ensuring the best quality of life for patients with MDD. Additionally, a randomized controlled study of a customized treatment for depression demonstrated an improvement in symptoms and fewer adverse effects in a large percentage of participants.

Predictors of side effects

A major obstacle in individualized depression treatment is predicting which antidepressant medications will have minimal or no side effects. Many patients are prescribed a variety drugs before they find a drug that is both effective and well-tolerated. Pharmacogenetics offers a fascinating new avenue for a more effective and precise approach to selecting antidepressant treatments.

There are many predictors that can be used to determine the antidepressant to be prescribed, including genetic variations, phenotypes of patients such as ethnicity or gender, and the presence of comorbidities. To determine the most reliable and valid predictors of a specific treatment, randomized controlled trials with larger samples will be required. This is due to the fact that it can be more difficult to identify the effects of moderators or interactions in trials that only include one episode per person rather than multiple episodes over time.

Additionally, the prediction of a patient's reaction to a particular medication is likely to need to incorporate information regarding comorbidities and symptom profiles, and the patient's previous experiences with the effectiveness and tolerability of the medication. At present, only a few easily measurable sociodemographic and clinical variables appear to be correlated with the response to MDD like gender, age race/ethnicity BMI and the presence of alexithymia and the severity of depression symptoms.

There are many challenges to overcome in the application of pharmacogenetics in the treatment of depression treatment plan. It is crucial to have a clear understanding and definition of the genetic mechanisms that underlie depression, and an understanding of a reliable predictor of treatment response. In addition, ethical issues such as privacy and the responsible use of personal genetic information must be considered carefully. Pharmacogenetics could eventually, reduce stigma surrounding treatments for mental illness and improve private treatment for depression outcomes. But, like any other psychiatric treatment, careful consideration and implementation is essential. At present, it's recommended to provide patients with an array of depression medications that are effective and encourage them to speak openly with their doctor.